ANDOVER, Mass.--(BUSINESS WIRE)--ndd Medical Technologies, Inc. announced that the company’s EasyOne Pro® provided highly accurate and stable pulmonary gas exchange measurements for patients across the 21 sites of the National Institutes of Health (NIH)’s COPDGene clinical trial. The COPDGene® trial chose and uses the EasyOne Pro as the exclusive DLCO testing device in the second phase of the study. More than 2,000 patients have been tested in Phase II using ndd’s advanced ultrasound-based mobile pulmonary function testing (PFT) device.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
